Traws Pharma
TRAW
12 hedge funds and large institutions have $3.8M invested in Traws Pharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 17 closing their positions.
180% more capital invested
Capital invested by funds: $1.36M → $3.8M (+$2.45M)
34.84% more ownership
Funds ownership: 0.48% → 35.32% (+35%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
57% less funds holding
Funds holding: 28 → 12 (-16)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$5.13M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$19.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.17K |
| 4 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$64 |
| 5 |
BlackRock
New York
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$100K |
| 2 |
Renaissance Technologies
New York
|
-$97.4K |
| 3 |
MG
Marex Group
London,
|
-$66.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$54.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$30.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| – | -$137 | -12 | Closed |
|
27
JP Morgan Chase
New York
| – | -$25 | -2 | Closed |
|
28
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1 | – | – |
|
TRAW Hedge Fund Activity: Q3 2024 in Review
12 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2024, worth a combined $3.8M — up 180% from $1.36M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TRAW and 1 opened new positions — a net loss of 16 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was OrbiMed, adding an estimated $5.13M. The largest seller was Geode Capital Management, exiting entirely with an estimated $100K sold.
- 12 institutional investors held Traws Pharma (TRAW) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $3.8M of Traws Pharma stock for Q3 2024, up 180% quarter-over-quarter.
- 1 fund opened new Traws Pharma positions in Q3 2024 and 17 closed out, a net change of -16 holders.
- The largest Traws Pharma buyer in Q3 2024 was OrbiMed, an estimated $5.13M added.
- The largest Traws Pharma seller in Q3 2024 was Geode Capital Management, an estimated $100K sold.
Based on aggregated 13F filings for Q3 2024.